November 29, 2018

Collaboration driven by the Leukemia & Lymphoma Society to expedite development of innovative therapies for Acute Myeloid Leukemia Patients

In 2016, the Leukemia & Lymphoma Society (LSS) in partnership with the FDA, leading leukemia MDs in North America, and several biopharmaceutical companies finalized plans for a groundbreaking platform “umbrella” trial—Beat AML—with an ambitious goal to speed development of targeted therapies for newly diagnosed patients with acute myeloid leukemia (AML). Within a single “Master Trial” built to initially support up to 10 different protocols, researchers aim to identify subsets of treatment-naïve AML patients based on NGS testing for known key mutational drivers, and target them with novel agents directed against those mutations. For patients with multiple mutations, advanced analytics including VAF (variant allele frequency) and a predetermined prioritization schema then steers each patient to the best sub-study.